Results 1 to 10 of about 1,844 (180)

Mavacamten facilitates myosin head ON-to-OFF transitions and shortens thin filament length in relaxed mouse skeletal muscle. [PDF]

Physiol Rep
The first‐in‐its‐class cardiac drug mavacamten shifts myosin heads towards a structurally inactive position where they lay along the helical tracks of the thick filament.
Kuehn MN, Engels NM, Nissen DL, Freundt JK, Ma W, Harris SP, Irving TC, Linke WA, Hessel AL.   +8 more
europepmc   +3 more sources

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Cardiac myosin inhibitors have been shown to improve diastolic function in patients with obstructive hypertrophic cardiomyopathy (HCM). Comparative studies to evaluate the diastolic effects of mavacamten versus alcohol septal ablation (ASA) have yet to ...
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +2 more sources

Mavacamten

JACC: Advances
Matthew W. Martinez, MD, Dewey Seto, BSBA, Michael Cheung, DHSc, Michele Coiro, MBA, Niki Patel, PharmD, Arnaud Bastien, MD, Jeffrey Lockman, PhD, Sonia Afsari, MD, Milind Y. Desai, MD, MBA   +8 more
doaj   +11 more sources

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Mahana I, Mejia AT, Elman MR, Kamna D, Nguyen O, Volk H, Chen H, Masri A.   +7 more
europepmc   +2 more sources

Real-World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification. [PDF]

J Am Heart Assoc
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Desai MY, Gaballa A, Okushi Y, Abusafia M, Jadam S, Rutkowski K, Ospina S, Sultana S, Thamilarasan M, Asher C, Popovic ZB, Xu B.   +11 more
europepmc   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM [PDF]

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +3 more sources

Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy. [PDF]

Front Cardiovasc Med
AimsTo provide real-world data on the symptomatic and hemodynamic response of the myosin inhibitor mavacamten in patients with hypertrophic obstructive cardiomyopathy (HOCM).MethodsPatients with HOCM up-titrated to their final mavacamten dose were ...
Seuthe K, Feidakis A, Nies R, Brüwer M, Pennig L, Kaya K, Ten Freyhaus H, Baldus S, Pfister R.   +8 more
europepmc   +2 more sources

ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy. [PDF]

Open Heart
Background Mavacamten has revolutionised the treatment of hypertrophic obstructive cardiomyopathy (HOCM) but requires frequent follow-up. Routine ECG may offer an accessible tool to indicate response to therapy.
Buehning F, Lerchner T, Vogel J, Kolk L, Vogel L, Seuthe K, Ferdinandy P, Mahabadi AA, Rassaf T, Michel L.   +9 more
europepmc   +2 more sources

Pharmacogenetic testing to broaden patient eligibility for mavacamten [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy
The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive
Olivotto, Iacopo
core   +4 more sources

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges. [PDF]

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Kukowka A, Droździk M.
europepmc   +2 more sources